medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2014, Number 2

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2014; 30 (2)

Immunological disorders in Castleman's disease

Alfonso VME, Fernández ÁJD, del Valle PLO, Bencomo HA, Macías AC

Language: Spanish
References: 21
Page: 184-189
PDF size: 93.27 Kb.


ABSTRACT

Castleman'sdisease is a rare disorder characterized by angiofollicularlymphoid hyperplasia. There are two main histological patterns of the disease: the hyaline vascular type and the plasma cell type; andtwo clinical forms: localized and multicentric. We report a case of a 19-year-old female patient with hyaline vascular typeCastleman's disease withcervical lymphadenopathies and medical history of repetitive infectious diseases before diagnosis. The inmunohistochemical study reported CD 20, normal pattern of CD3 and Ki 67 positive only in lymphoidfollicles. The immunological study showed low levels of CD3+ CD4+ lymphocytes, slightly low levels of CD3+ CD8+ lymphocytes, and the presence of antinuclear antibodies (ANA). The humoral immunity was not affected.Other findings were IgG antibodies against CMV and EBV positive, and VIH 1,2 antibodies negative. Clinical history suggesting Immunodeficiency and laboratory findingssupport the hypothesis that deregulation of the immune system could lead to the pathogenesis of the proliferative disease. Also, the immunodeficiency state promotes the onset of opportunistic infectionswhich may increase immune and proliferative disorders. A favorable response to immunostimulant treatment was observed.


REFERENCES

  1. Sarrot-Reynauld F. Castleman´s Disease. Orphanetencyclopedia, Ag 2001. [acceso: 24 de mayo de 2013]. Disponible en: http://www.orpha.net/data/patho/GB/ukcastleman. pdf

  2. Espinosa Estrada E, Hernández Cabezas A, Hernández Padrón C, Ramón Rodríguez L, Ávila Cabrera O, Izquierdo Cano L, et al. Anemia drepanocítica y enfermedad de Castleman. Rev Cubana Hematol Inmunol Hemoter, 2012;28(1):77-83.

  3. Nicoli P, Familiari U, Bosa M, Allice T, Mete F, Morotti A, et al. HHV8-positive, HIV-negative multicentric Castleman's disease: early and sustained complete remission with rituximab therapy without reactivation of Kaposi sarcoma. Int J Hematol. 2009 Oct;90(3):392-6.

  4. Viveros ALM, Sánchez MJF. Enfermedad de Castleman. Reporte de un caso en adolescente. An Med Asoc Med Hosp ABC 2001;46(4):193-6.

  5. Sepúlveda M, Contreras E, Martínez N. Enfermedad de Castleman. Descripción de un caso clínico. Rev Venez Oncol. 2008;20(2):104-7.

  6. Castilletti JM, Vargas DM, Martínez M, Rojas N. Enfermedad de Castleman. A propósito de dos casos. Archivos venezolanos de puericultura y pediatría 2008;71(2):54-8.

  7. Dispenzieri A, Gertz MA. Treatment of Castleman's disease. Curr Treat Options Oncol. 2005 May;6(3):255-66.

  8. Chen XF, Han H, Li YH, Zhang Y, Qin ZK, Liu ZW, et al. Local Castleman's disease: a report of 17 cases with literature review. Ai Zheng. 2008 Mar;27(3):315-8.

  9. Chen CC, Jiang RS, Chou G, Wang CP. Castleman'sdisease of the neck. J Chin Med Assoc. 2007 Dec;70(12):556-8.

  10. Aguiar MR, Acevedo PA, Staffieri R. Enfermedad de Castleman: Presentación de un caso clínico. Anuario Fundación Dr. JR Villavicencio. 2008 [acceso: 24 de mayo de 2013];(XVI):176-7. Disponible en: http://www.villavicencio.org.ar/pdf08/176.pdf

  11. Van Rhee F, Stone K, Szmania S, Barlogie B, Singh Z. Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy. Clin Adv Hematol Oncol. 2010 Jul;8(7):486-98.

  12. Mylona EE, Baraboutis IG, Lekakis LJ, Georgiou O, Papastamopoulos V, Skoutelis A. Multicentric Castleman's disease in HIV infection: a systematic review of the literatura. AIDS Rev. 2008 Jan-Mar;10(1):25-35.

  13. Flejsierowicz M, Ahmed MS, Kotov P, Cheng YC. Successful treatment of aggressive HIV-associated multicentric Castleman's disease: a case report. WMJ 2008 Jul;107(4):191-4.

  14. Gholam D, Vantelon JM, Al-Jijakli A, Bourhis JH. A case of multicentric Castleman's disease associated with advanced systemic amyloidosis treated with chemotherapy and anti-CD20 monoclonal antibody. Ann Hematol. 2003. Dec;82(12):766-8.

  15. Waterston A, Bower M. Fifty years of multicentricCastleman's disease. Acta Oncol. 2004;43(8):698-704.

  16. Pastor MA, Vasco B, Mosquera JM, Debén G, Bautista P, Requena L. Two HHV8- related illnesses in a HIV-negative patient: Kaposi's sarcoma and multicentric Castleman's disease. Response to treatment with Rituximab and CHOP. Actas Dermosifiliogr 2006 Jul-Aug;97(6):385-90.

  17. López I, Gázquez A, Martín M. Rubio A. Enfermedad de Castleman localizada en región cervical. An Med Intern (Madrid). 2003;2(12):651-2.

  18. Bannura G, Soto D, Cornejo V. Enfermedad de Castleman rectal: reporte de un caso del tipo hialino-vascular. Rev Chilena de Cirugía. 2007 Dic;59(6):463-6.

  19. Sobrevilla Calvo PJ, Avilés Salas A, Cortés Padilla DE, Rivas Vera S. Características clinicopatológicas de la enfermedad de Castleman. Experiencia en el Instituto Nacional de Cancerología. Cir Ciruj. 2009 [acceso: 28 de mayo de 2013];77:187-92. Disponible en: http://circiruj.edilaser.net/es/pdf/7703/2009-77-03-187-192.pdf

  20. About Castleman's Disease. International Castleman disease organization. [acceso: 28 de mayo de 2013]. Disponible en: http://www.castlemans.org/about

  21. Cazorla AC, Hernández Mora MG, Fernández M, Renedo G, Rivas C. Enfermedad de Castleman multicéntrica en Sida. Su relación con el VHH-8 o virus herpes asociado al sarcoma de Kaposi. Estudio de dos casos. Rev Clin Esp. 2005:205(12);607-9.




2020     |     www.medigraphic.com